President Trump recently signed a bill that funds the federal government, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the U.S. Food and Drug Administration (FDA), for Fiscal Year (FY) 2020. Importantly, the bill also raises the purchasing age of tobacco products to 21.
Howard A. “Skip” Burris III, MD, FACP, FASCO
“A longtime advocate on this issue, ASCO believes this important change will delay and reduce the use of tobacco and help prevent tobacco-related cancers,” ASCO President Howard A. “Skip” Burris III, MD, FACP, FASCO, said in a statement. “We commend Congress for taking this important step and look forward to continuing to work with lawmakers and regulators in service of our longstanding commitment to reducing and eventually eliminating tobacco-related cancers.”
Overview of Funding for FY2020
The bill provides a $2.6 billion increase for the NIH, bringing the total funding level to $41.7 billion. The NCI receives $6.44 billion—nearly a $300 million increase from FY2019. The bill also provides full funding for the Beau Biden Cancer Moonshot and the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act, which enhances opportunities to expand research on childhood cancer and increases efforts to improve quality of life for pediatric cancer survivors.
To address the skyrocketing number of grant applications to the NCI, the bill provides $212.5 million to prioritize competing grants and sustain commitments to continuing grants.
The bill also includes:
ASCO will continue to advocate for continued investment in federally funded cancer research and will work with congressional lawmakers as they begin deliberations on FY2021 funding levels, which is expected to kick off early this year.
Visit asco.org/ascoaction to stay up to date on all oncology policy priorities. ν
© 2020. American Society of Clinical Oncology. All rights reserved.